secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0001104659-25-044240
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros gets additional Nasdaq delisting notice for Feb 2025 offering; completes 1-for-25 reverse split
--------------------------------------------------------------------------------

- Nasdaq notified Petros on April 28 of public interest concerns regarding its February 19, 2025 public offering as a new delisting basis under Rule 5810(d).
- Company intends to address concerns before a Nasdaq Hearings Panel; delisting actions are stayed pending the hearing.
- 1-for-25 reverse stock split effective 4:05 pm ET April 30, 2025; split-adjusted trading began May 1, 2025, under same symbol PTPI.
- No fractional shares issued; authorized shares remain 7 billion; proportionate adjustments made to options and equity plan.
- New CUSIP number is 71678J308; the reverse split does not immediately affect trading.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/0001104659-25-044240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465925044240/tm2513449d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-044240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer